Skip to content

menu

Health Law Pulse logo
HomeAboutContact
Search
Close
RegulatoryEnforcementFDA & Food SafetyTransparencyInternational
View topics Archives
Subscribe

Health Law Pulse

Leading insight on legal developments in the healthcare and life sciences industries.

Medicare Part D

Subscribe to Medicare Part D via RSS

OIG proposes to eliminate safe harbor protection for drug manufacturer rebates to PBMs; proposes two new safe harbors

Posted on February 5, 2019

On January 31, the Department of Health and Human Services (HHS) Office of Inspector General (OIG) issued a proposed new rule that, if finalized, would eliminate existing protection under the Anti-Kickback Statute (AKS) “discount” safe harbor (42 C.F.R. 1001.952(h)) for…

Centers for Medicare & Medicaid Services finalizes policies and updates to Medicare Advantage and Part D programs for 2019

Photo of Jeff Wurzburg (US)
By Jeff Wurzburg (US) on April 10, 2018

On April 2, 2018, CMS released the 2019 Rate Announcement and Final Call Letter (Call Letter) and published an expansive final rule containing updates to policies for Medicare Advantage (MA) and the Medicare Part D Prescription Drug Program (Part D).  …

Subscribe to Health Law Pulse

Subscribe to this publication

Centers for Medicare & Medicaid Services proposes policies and updates to Medicare Advantage and Part D programs for 2019

Photo of Jeff Wurzburg (US)
By Jeff Wurzburg (US) on February 6, 2018

On February 1, 2018, the Centers for Medicare & Medicaid Services (CMS) proposed changes to the Medicare Advantage and Part D programs through the Advance Notice and Draft Call Letter (Advance Notice) for calendar year 2019.  As required by section…

Health Law Pulse

Facebook Twitter RSS LinkedIn YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date on healthcare enforcement and regulations with the Health Law Pulse. We give you the news and analysis that matter to your business in a quick, easy-to-read format.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.